Persistent elevated serum levels of intact parathyroid hormone after reoperation for primary hyperparathyroidism and after pamidronate therapy.

Primary hyperparathyroidism is a life-threatening rare disorder. It is seen as a result of neonatal primary hyperparathyroidism, familial hypocalciuric hypercalcemia, increased vitamin D levels and inactivation of calcium sensing receptor mutations. The clinical findings are hypotonia, bone demineralization, hypercalcemia and parathyroid hyperplasia. We present a six-month-old female patient, the first child of nonconsanguineous parents, who was referred for the investigation of failure to thrive, vomiting, constipation, fever, abdominal distention and hypotonia. Physical examination revealed weight under 3rd percentile, height 3rd-10th percentile, decreased subcutaneous fat, and distention of the abdomen. In neurological examination, hypotonia, motor-mental retardation, and active deep tendon reflexes were found. The biochemical values at the time of admission revealed primary hyperparathyroidism. Since hypercalcemia did not respond to calcitonin therapy and due to the mortality of hypercalcemia, parathyroidectomy was performed. Because hyperparathyroidism and hypercalcemia continued, angiography was done which revealed increased parathyroid hormone levels in the periphery of the innominate vein. Exploratory surgery followed, but hyperparathyroidism and hypercalcemia persisted after all of these procedures. Calcium-sensing receptor mutations and supernumerary gland were considered. Because hypercalcemia persisted, pamidronate therapy was initiated on a monthly basis.

[1]  S. Silverberg,et al.  CHAPTER 23 – Clinical Course of Primary Hyperparathyroidism , 2001 .

[2]  F. Glorieux,et al.  Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. , 2000, The Journal of clinical endocrinology and metabolism.

[3]  M. Raffaelli,et al.  [Supernumerary ectopic hyperfunctioning parathyroid gland: a potential pitfall in surgery for sporadic primary hyperthyroidism]. , 2000, Annales de chirurgie.

[4]  R. Ziegler,et al.  [Effect of pamidronate on clinical symptoms and bone metabolism in fibrous dysplasia and McCune-Albright syndrome]. , 1998, Medizinische Klinik.

[5]  H. Tanaka,et al.  Two novel missense mutations in calcium-sensing receptor gene associated with neonatal severe hyperparathyroidism. , 1997, The Journal of clinical endocrinology and metabolism.

[6]  S. Goldfischer Childhood cancer and hypercalcemia: Report of a case treated with pamidronate , 1997 .

[7]  S. Pearce,et al.  Calcium-sensing receptor mutations in familial benign hypercalcemia and neonatal hyperparathyroidism. , 1995, The Journal of clinical investigation.

[8]  P. Delmas,et al.  Long‐Term Effects of Intravenous Pamidronate in Fibrous Dysplasia of Bone , 1997, Lancet.

[9]  P. Delmas,et al.  Long-term effects of intravenous pamidronate in fibrous dysplasia of bone , 1994, The Lancet.

[10]  D. McTavish,et al.  Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. , 1991, Drugs.

[11]  K. Lillquist,et al.  [Familial hypocalciuric hypercalcemia]. , 1985, Ugeskrift for læger.

[12]  R. Lasker,et al.  An association between neonatal severe primary hyperparathyroidism and familial hypocalciuric hypercalcemia in three kindreds. , 1982, The New England journal of medicine.

[13]  E. Orwoll,et al.  Asymptomatic neonatal familial hypercalcemia. , 1982, Pediatrics.